NEW YORK, November 14 /PRNewswire/ --

Xenomics, Inc. (the "Company") (OTC Pink Sheets: XNOM; FWB: XE7) a developer of next-generation medical DNA diagnostic technologies, announced today issuance of its US patent "Methods for detection of nucleic acid sequences in urine," RE39,920 that covers use of its proprietary transrenal nucleic acid technology in the area of infectious disease diagnostics and monitoring.

Transrenal nucleic acids (Tr-DNA and Tr-RNA) are fragments of DNA and RNA from cells dying throughout the body that cross the kidney barrier from blood to urine and can be used for genetic analysis. Xenomics' previous patents covered applications of the Tr-NA technology for prenatal genetic testing, tumor diagnostics and monitoring, and detection of rejection episodes after organ transplantation. The new patent covers diagnosis and monitoring of infectious diseases, the most rapidly growing area of molecular diagnostics.

The molecular diagnostic segments in general are projected to outperform the overall diagnostics market, growing from US$13.8 billion in 2005 to US$22.7 billion in 2010. Currently, the largest market application segment for molecular diagnostics is infectious disease testing.

Xenomics' scientists have detected in urine DNA and RNA fragments of different pathogens, including viruses, bacteria and parasites, that infected organs and tissues located outside of urinary system. Pulmonary tuberculosis, malaria, leishmania, HIV, H. pylori-induced ulcers of stomach and duodenum, cervical cancer caused by HPV (Human Papilloma Virus) are only some examples of diseases where the Tr-NA technology can be applied.

"The issuance of this patent significantly enhances our patent portfolio," commented Gianluigi Longinotti-Buitoni, Executive Chairman of Xenomics. "It is especially important for us now when several clinical tests for diagnosis of infectious diseases as well as for detecting tumors caused by viral infections are under development at Xenomics."

About Xenomics, Inc.

Xenomics is a molecular diagnostics company that focuses on the development of DNA-based tests using Transrenal DNA (Tr-DNA). Xenomics' patented technology uses safe and simple urine collection and can be applied to a broad range of applications, including prenatal testing, tumor detection and monitoring, tissue transplantation, infectious disease detection, genetic testing for forensic identity determination, drug development, and research to counter bioterrorism. Scientists from Xenomics were the first to report that fragments of DNA from normal cell death cross the kidney barrier and can be detected in urine. The Company believes that its technology will open significant new markets in the molecular diagnostics field. Xenomics has three issued U.S. patents covering different applications of the technology for molecular diagnostics and genetic testing and a European patent for the Company's prenatal testing applications, and numerous pending patent applications. For more investor-specific information, including daily and historical Company stock quote data, recent news releases and an Investor Fact Sheet, please visit http://www.xenomics.com. Xenomics is also listed on the Frankfurt Stock Exchange under the symbol XE7.

Forward-Looking Statements

Certain statements made in this press release are forward looking. Such statements are indicated by words such as "expect," "might," "should," "anticipate" and similar words indicating uncertainty in facts and figures. Although Xenomics believes that the expectations reflected in such forward-looking statements are reasonable, it can give no assurance that such expectations reflected in such forward-looking statements will prove to be correct. As discussed in Xenomics' Form 10-KSB as filed with the Securities and Exchange Commission on May 16, 2006 and its other periodic reports, actual results could differ materially from those projected in the forward-looking statements as a result of the following factors, among others: uncertainties associated with product development, the risk that Xenomics will not obtain approval to market its products, the risk that Xenomics' technology will not gain market acceptance, the risks associated with dependence upon key personnel, and the need for additional financing.

CONTACT: Samuil Umansky Xenomics, Inc. +1-732-438-8290 ext. 201 sumansky@xenomics.com

Web site: http://www.xenomics.com

Samuil Umansky of Xenomics, Inc., +1-732-438-8290, ext. 201, sumansky@xenomics.com